文献速递心力衰竭与心肌病冠心病血脂与心血管预防

恩格列净在EMPA-REG OUTCOME试验心衰风险谱中的心血管死亡与心衰住院效应

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
PubMed 文献 · Eur Heart J · 2018-01-01

基线无心衰者占89.9%,用Health ABC心衰风险评分分为低至中等、高和极高5年心衰风险组,恩格列净对心血管死亡和心衰住院的效应在各风险组中一致。

要点

  • 基线无心衰患者中67.2%为低至中等风险,24.2%高风险,5.1%极高风险。
  • 恩格列净降低心血管死亡和心衰住院的HR在低至中等、高、极高风险组分别为0.71、0.52和0.55。
  • 在基线心衰和/或试验期间发生心衰的最高风险组,恩格列净对心血管死亡也有益(HR 0.67)。

核心结论

  • 在2型糖尿病合并心血管疾病患者中,相当比例基线无心衰者存在高或极高心衰风险,提示需积极筛查。
  • 恩格列净在低或高心衰风险患者中均一致改善心衰结局。

研究设计与样本

  • 基线无心衰患者(89.9%)采用9变量Health ABC心衰风险评分评估5年新发心衰风险,分为低至中等(<10%)、高(10-20%)和极高(≥20%)三组。

主要发现

  • 总体人群中67.2%为低至中等5年心衰风险,24.2%为高风险,5.1%为极高风险。
  • 恩格列净对心血管死亡和心衰住院的效应在各风险组一致:低至中等风险组HR 0.71(95%CI 0.52, 0.96),高风险组HR 0.52(95%CI 0.36, 0.75),极高风险组HR 0.55(95%CI 0.30, 1.00)。
  • 在基线心衰和/或试验期间发生心衰的最高风险组(占总体心血管死亡的37.9%),恩格列净对心血管死亡有益(HR 0.67,95%CI 0.47, 0.97),较低风险患者也见类似获益。

关键数值与推荐

  • 原文未报告具体推荐条款。

临床怎么用

  • 对2型糖尿病合并心血管疾病患者,应使用心衰风险评分识别高或极高心衰风险者,即使基线无心衰。
  • 恩格列净可考虑用于降低心血管死亡和心衰住院风险,无论基线心衰风险高低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME® trial. We investigated whether the benefit of empagliflozin was observed across the spectrum of HF risk. METHODS AND RESULTS: Seven thousand and twenty patients with T2D (HbA1c 7-10% and eGFR > 30 mL/min/1.73 m2) were treated with empagliflozin 10 or 25 mg, or placebo once daily and followed for median 3.1 years. In patients without HF at baseline (89.9%), we derived the 5-year risk for incident HF using the 9-variable Health ABC HF Risk score [classified as low-to-average (<10%), high (10-20%), and very high (≥ 20%)]. Overall, 67.2% of the population had low-to-average, 24.2% high, and 5.1% very high 5-year HF risk. Across these groups, the effect on CV death and HF hospitalization with empagliflozin was consistent [hazard ratio 0.71 (95% confidence interval: 0.52, 0.96), 0.52 (0.36, 0.75), and 0.55 (0.30, 1.00), respectively]. Effects on CV death in the ostensibly highest HF risk group (HF at baseline and/or incident HF during the trial) in whom 37.9% of the overall CV deaths occurred, was also beneficial [0.67 (0.47, 0.97)], yet, similar benefits were seen in the lower risk patients. CONCLUSION: In patients with T2D and established CVD, a sizeable proportion without HF at baseline are at high or very high risk for HF outcomes, indicating the need for active case finding in this patient population. Empagliflozin consistently improved HF outcomes both in patients at low or high HF risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018. PMID: 29020355. doi:10.1093/eurheartj/ehx511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。